Very sensible analysis mal85, been following Xero story and your take on it from time to time.
My observation is that Xero have been investing in payroll (bought Monchilla in 2014) and now they've bitten the bullet by impairing it (the market seems to have shrugged off the fact that Xero made a net loss in 1H19, which is as large as the loss in all of the FY18).
Partnership terms with Gusto are not yet clear, there is no information regarding pricing.
Judging by 94 comments on Xero's blog, customers aren't happy with the potential extra cost for a payroll feature they felt was actually working fine.
What's your view on payroll dilemma and likely effect on churn rates and customer growth in US?
- Forums
- ASX - By Stock
- Ann: Investor Presentation H1 FY19
Very sensible analysis mal85, been following Xero story and your...
-
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add XRO (ASX) to my watchlist
|
|||||
Last
$135.87 |
Change
2.340(1.75%) |
Mkt cap ! $20.59B |
Open | High | Low | Value | Volume |
$133.87 | $135.87 | $133.73 | $39.94M | 295.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 308 | $135.84 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$135.89 | 360 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 308 | 135.840 |
1 | 120 | 135.790 |
1 | 43 | 135.780 |
2 | 404 | 135.770 |
1 | 137 | 135.710 |
Price($) | Vol. | No. |
---|---|---|
135.890 | 360 | 1 |
135.900 | 1210 | 4 |
135.920 | 496 | 1 |
135.980 | 356 | 1 |
135.990 | 200 | 1 |
Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
Featured News
XRO (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online